cardiovascular events in patients with chronic lymphocytic leukemia (cll) - asco 2022
Published 9 months ago • 81 plays • Length 7:12Download video MP4
Download video MP3
Similar videos
-
7:00
survival rate in chronic lymphocytic leukemia (cll) patients treated at academic centers - asco 2022
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
5:12
preclinical research of menin inhibitor for chronic lymphocytic leukemia (cll) - asco 2022
-
1:21
cardiovascular adverse events following treatment with btk inhibitors in cll & mcl
-
12:53
selecting first-line treatment for chronic lymphocytic leukemia (cll)
-
6:14
ibrutinib plus venetoclax for treatment of cll (chronic lymphocytic leukemia) - asco 2022
-
0:57
unanswered questions in frontline cll treatment
-
1:12
covid-19 infection in patients with cll
-
1:16
venetoclax for the treatment of elderly patients with cll
-
6:04
obinutuzumab, ibrutinib, and venetoclax for cll (chronic lymphocytic leukemia) treatment - asco 2022
-
2:01
the role of mrd in cll patients with high-risk cytogenetics & future perspectives
-
3:37
identifying patients with cll at a high risk of developing cardiotoxicity with btk inhibitors
-
0:47
preliminary safety and efficacy of enitociclib in patients with nhl & cll
-
1:57
addressing cardiovascular aes associated with btki treatment in patients with cll
-
1:22
exciting drug developments in chronic lymphocytic leukemia (cll)
-
1:48
patient risk stratification in cll and selection of treatment approaches
-
7:53
racial and socioeconomic disparities among chronic lymphocytic leukemia (cll) patients - asco 2022
-
3:23
advances in the treatment of cll at asco 2015
-
1:48
characterizing the development of mds in patients with cll in the era of targeted therapies